JTV-263
Peripheral artery disease
Phase1Active
Key Facts
About Akros Pharma
Akros Pharma is a clinical-stage biotechnology company serving as the US development arm of Shionogi. Its pipeline consists of seven small molecule drug candidates, primarily in Phase 1 and Phase 2 trials, targeting autoimmune diseases, type 2 diabetes, chronic heart failure, neurodegenerative diseases, pulmonary arterial hypertension, and peripheral artery disease. The company leverages Shionogi's discovery engine and is led by a management team with deep expertise in clinical development, regulatory affairs, and intellectual property. As a private, subsidiary entity, its financial position and strategic direction are intrinsically linked to its parent company.
View full company profileTherapeutic Areas
Other Peripheral artery disease Drugs
| Drug | Company | Phase |
|---|---|---|
| Ranger™ Drug-Coated Balloon | Boston Scientific | Approved/Commercial |
| Eluvia™ Drug-Eluting Vascular Stent | Boston Scientific | Approved/Commercial |
| Peripheral Artery Disease Program | Elixir Medical | Pre-clinical |
| Aperta NSE™ PTA | Nipro Medical | Commercial |
| Luminor DCB | iVascularU | Post-Market |
| iVolution pro Stent | iVascularU | Post-Market |
| FGF-1 | Zhittya Genesis Medicine | Phase 2 |